Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2006

Dyax and Trubion Collaborate on Therapeutics and Diagnostics Discovery

  • Dyax entered into a nonexclusive agreement with Trubion Pharmaceuticals in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion’s targets in the oncology and inflammation area.

    Dyax will receive upfront and FTE payments from Trubion, as well as technical and development milestone payments and royalties on net sales of any products that may result from Trubion’s development and commercialization of binding regions from Dyax’ libraries. The agreement also provides Trubion with an option to license Dyax’ phage display libraries.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »